Literature DB >> 11883950

Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin.

Jong Tae Kim1, Eun Mi Kim, Kyoung Hoa Lee, Ji-Eun Choi, Byung H Jhun, Jung Woo Kim.   

Abstract

Interactions between viral and cellular proteins could explain the molecular mechanisms behind the viral life cycle of HIV-1. The envelope protein gp41 of HIV-1 specifically interacted with alpha-catenin, not with beta-catenin. This interaction was shown by in vitro protein assay and in vivo transfected cell systems. Microinjection of the DNA expressing HIV-1 gp160 and alpha-catenin, into the HeLa cell, resulted in the colocalization of gp41 and alpha-catenin. Interestingly the noncleavable mutant of gp160 and alpha-catenin were found to be colocalized in the cell membrane. Mapping of the interaction sites between these two proteins revealed that the leucine zipper-like structure, located between the first and second alpha-helix domains from the carboxy terminus of HIV-1 gp41, interacted strongly with the carboxy terminus of alpha-catenin. (C)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883950     DOI: 10.1006/bbrc.2002.6583

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Modulation of gene expression in CD4+ T lymphocytes following in vitro HIV infection: a comparison between human and chimpanzee.

Authors:  Pol-André Apoil; Arnaud Gleizes; Bénédicte Puissant-Lubrano; Lionel Forestier; Raymond Julien; Peter Winterton; Christophe Pasquier; Jacques Izopet; Antoine Blancher
Journal:  Virusdisease       Date:  2015-06-06

Review 2.  HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Eric O Freed
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

3.  Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein.

Authors:  Vanessa Emerson; Denise Holtkotte; Tanya Pfeiffer; I-Hsuan Wang; Martina Schnölzer; Tore Kempf; Valerie Bosch
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

4.  GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.

Authors:  Alenka Jejcic; Stefan Höglund; Anders Vahlne
Journal:  Retrovirology       Date:  2010-03-15       Impact factor: 4.602

Review 5.  The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.

Authors:  Thomas S Postler; Ronald C Desrosiers
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles.

Authors:  Jayanta Bhattacharya; Paul J Peters; Paul R Clapham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  Cholesterol depletion of human immunodeficiency virus type 1 and simian immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes the virions: evidence for virion-associated lipid rafts.

Authors:  David R M Graham; Elena Chertova; Joanne M Hilburn; Larry O Arthur; James E K Hildreth
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Retroviral env glycoprotein trafficking and incorporation into virions.

Authors:  Tsutomu Murakami
Journal:  Mol Biol Int       Date:  2012-07-02

9.  Generation of H9 T-cells stably expressing a membrane-bound form of the cytoplasmic tail of the Env-glycoprotein: lack of transcomplementation of defective HIV-1 virions encoding C-terminally truncated Env.

Authors:  Denise Holtkotte; Tanya Pfeiffer; Valerie Bosch
Journal:  Retrovirology       Date:  2006-05-16       Impact factor: 4.602

10.  Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.

Authors:  Stephen A Gallo; Jacqueline D Reeves; Himanshu Garg; Brian Foley; Robert W Doms; Robert Blumenthal
Journal:  Retrovirology       Date:  2006-12-04       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.